Advances in Cancer Immunotherapy™ - San Francisco, CA

Saturday, May 6, 2017, 8:00 AM - 2:00 PM (UTC-8:00) Pacific Time (US & Canada)

sitc_log_color.pngOrganizers:
Alain Algazi, MD – University of California, San Francisco
Michael Buljan, NP – University of California, San Francisco
Adil Daud, MD – University of California, San Francisco

Share This Event Flyer With Your Network

Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE- and CNE-certified programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, these six-hour programs will facilitate understanding of:

  • The rationale for common approaches to immunotherapy
  • The clinical applications of immunotherapy for disease states with FDA-approved treatments (melanoma, and lung, genitourinary, hematologic, and head and neck cancers)
  • Operational and reimbursement barriers to implementing immunotherapy in a community setting and strategies to overcome them
  • The identification and management of immune-related adverse events from the nursing and prescriber perspective in the clinic and emergency settings

Attendees will also have the opportunity to connect to regional experts in the immunotherapy field at the live event, through two Immuno-Oncology (IO) Cup o' Joe webinars after the program, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice. Breakfast and lunch will be served at the live portion of this event.

Update: The IO Cup o' Joe webinars have been scheduled. The webinars will provide clinicians the opportunity to ask questions and receive guidance about immuno-oncology. Mark your calendars for these following dates:

  • Wednesday, June 14, Noon - 1 p.m. PT
  • Tuesday, August 8, Noon - 1 p.m. PT

Information on how to register for the webinars will be sent to program attendees via email.

For more information, including program objectives, click here.

This program is presented in collaboration with the American Academy of Emergency Medicine (AAEM) and the Association of Community Cancer Centers (ACCC).      

                    

 

 

Program Registration

Advance online registration for the Advances in Cancer Immunotherapy™ in San Francisco, CA is NOW CLOSED.

On-site registration will be available as space permits. You can find a PDF version of the registration form here.

SITC members are eligible for discounted registration rates. To receive discounted member rates, your membership dues must be current through 2017.

Click here to learn more about the registration rates for members and non-members for this program.

Program Agenda

Pre-Program Course: Online Immunology 101 for the Non-Immunologist (optional)

This online pre-program course on basic tumor immunology is optional, but strongly recommended for attendees new to tumor immunology to enhance their experience at the program on May 6.

May 6 Program

5.5 AMA PRA Category 1 Credits™ Click here for more detailed CME, CNE and CPE information and program objectives.

Presentations include time for Audience Response System (ARS)-assisted audience
interaction as well as general question and answer time.

7 – 8 a.m.

Check-in, Onsite Registration and Networking

Part A: Introduction to Incorporating Immunotherapy Into Clinical Practice

Session I: From Basic Principles to Clinical Applications of Cancer Immunotherapy

8 – 8:05 a.m.

Welcome, Introduction, and Pretest Questions by the Society for Immunotherapy of Cancer

8:05 – 8:35 a.m.

Basic Principles of Cancer Immunotherapy
Robert H. Pierce, MD – Fred Hutchinson Cancer Research Center

8:35 – 8:55 a.m.

Immunotherapy for the Treatment of Melanoma
Adil Daud, MD – University of California, San Francisco

8:55 – 9:15 a.m.

Immunotherapy for the Treatment of Lung Cancer
Matthew Gubens, MD, MS – University of California, San Francisco

9:15 – 9:35 a.m.

Immunotherapy for the Treatment of Genitourinary Cancers
Terence Friedlander, MD University of California, San Francisco

9:35 – 9:55 a.m

Immunotherapy for the Treatment of Hematologic Malignancies
Charalambos Babis Andreadis, MD, MSCE – University of California, San Francisco

9:55 – 10:15 a.m

Immunotherapy for the Treatment of Head and Neck Cancers
Alain Algazi, MD – University of California, San Francisco

10:15 – 10:25 a.m

 Break

Session II: Overcoming Barriers to Incorporating Immunotherapy Into Community Practice

10:25 – 10:30 a.m.

Information About the Society for Immunotherapy of Cancer Resources

10:30 – 11 a.m.

Effective Practices for Incorporating Immunotherapy Into Hospital Operations
Julie Kennerly, PharmD, MS, MHA, BCPS – Ohio State University Comprehensive Cancer Center

11 – 11:30 a.m.

Coverage and Reimbursement Challenges and Strategies
Julie Kennerly, PharmD, MS, MHA, BCPS – Ohio State University Comprehensive Cancer Center

11:30 – 11:35 a.m.

Take-Home Points for Part A

11:35 a.m. – noon

Lunch

Part B: Immune-Related Adverse Event (irAE) Management

noon – 12:20 p.m.

Mechanisms of Immune-Related Adverse Events
Mehrdad Matloubian, MD, PhD – University of California, San Francisco

12:20 – 12:50 p.m.

Nursing Perspective on irAEs: Patient Education, Monitoring and Management
Michael Buljan, NP – University of California, San Francisco

12:50 – 1:20 p.m.

Management and Mitigation of irAEs for Immunotherapy Prescribers
Mary Nakamura, MD – University of California, San Francisco

1:20 – 1:50 p.m.

Identification and Management of Immune-Related Adverse Events in the Emergency Setting
Thomas Tobin, MD, MBA, FAAEM – American Academy of Emergency Medicine Board of Directors

1:50 – 1:55 p.m.

Posttest Questions by the Society for Immunotherapy of Cancer

1:55 – 2 p.m.

Take-Home Points for Part B and Closing Remarks


The 2017 Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants from Aduro Biotech, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Merck & Co., Inc. and Prometheus Laboratories Inc.
 

Location

Embassy Suites by Hilton San Francisco Airport
250 Gateway Boulevard
South San Francisco, CA 94080

Tags

  • Cancer Research
  • Biomarkers
  • Disease
  • Genitourinary Cancer
  • Head and Neck Cancer
  • Hematologic Malignancies
  • Lung Cancer
  • Skin Cancer
  • Modality
  • In person Event
  • SITC Scientific Projects
  • Cancer Immunotherapy Guidelines
  • Source
  • Advances in Cancer Immunotherapy ACI
  • Therapies
  • Adverse Events
  • Cytokines
  • Immune Checkpoint Inhibitors
  • Toxicities
  • User Type
  • Allied Health
  • Clinician
  • Nurse
  • Oncologist
  • Patient
  • Patient Advocate
  • Pharmacist
  • Researcher
  • Year
  • 2017